Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on March 14th

Gilead Sciences, Inc. (NASDAQ:GILDGet Free Report) announced a quarterly dividend on Thursday, February 1st, Zacks reports. Investors of record on Friday, March 15th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Thursday, March 28th. This represents a $3.08 annualized dividend and a yield of 4.09%. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75.

Gilead Sciences has raised its dividend payment by an average of 3.3% annually over the last three years and has increased its dividend every year for the last 9 years. Gilead Sciences has a dividend payout ratio of 41.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $7.50 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 41.1%.

Gilead Sciences Stock Up 0.3 %

Shares of Gilead Sciences stock opened at $75.32 on Tuesday. The business has a 50-day moving average of $77.84 and a 200-day moving average of $77.52. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The company has a market capitalization of $93.83 billion, a PE ratio of 16.74, a P/E/G ratio of 0.95 and a beta of 0.18. Gilead Sciences has a 1-year low of $71.37 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the previous year, the business posted $1.67 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences will post 7.07 EPS for the current fiscal year.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Barclays cut their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Oppenheimer decreased their price target on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average price target of $85.36.

View Our Latest Analysis on Gilead Sciences

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,242 shares of company stock worth $1,277,726. Corporate insiders own 0.21% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Altshuler Shaham Ltd grew its stake in shares of Gilead Sciences by 7.0% during the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 121 shares during the last quarter. Rodgers Brothers Inc. grew its stake in shares of Gilead Sciences by 4.6% during the second quarter. Rodgers Brothers Inc. now owns 3,113 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 138 shares during the last quarter. Putnam Investments LLC grew its stake in shares of Gilead Sciences by 1.8% during the first quarter. Putnam Investments LLC now owns 8,067 shares of the biopharmaceutical company’s stock valued at $669,000 after purchasing an additional 142 shares during the last quarter. Bell Investment Advisors Inc boosted its stake in Gilead Sciences by 16.8% in the fourth quarter. Bell Investment Advisors Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 153 shares during the last quarter. Finally, McIlrath & Eck LLC boosted its stake in Gilead Sciences by 30.7% in the fourth quarter. McIlrath & Eck LLC now owns 736 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 82.33% of the company’s stock.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Dividend History for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.